Perspective Therapeutics Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.5% | -3.5% | -4.9% | +24.7% | +6.9% | -11.6% | +26.8% | +2.4% | +1.9% | -2.6% | +21.9% | +1.1% | +0.0% | +20.3% | -4.7% | +30.6% | -20.9% | +4.6% | -1.0% | +10.2% | +4.2% | +7.4% | -13.9% | -31.5% | +6.9% | -0.3% | -67.9% | +255.1% | -350.9% | – | +17.8% | +13.5% | -36.6% | +57.7% | -21.4% | -27.9% | -79.4% | +76.7% | +6.6% | – | |
| – | +3.1% | -11.5% | -0.4% | -3.9% | -11.8% | +8.5% | +6.2% | -4.1% | +21.0% | -11.0% | +9.7% | -8.3% | +0.0% | +3.3% | +1.5% | +7.2% | +2.9% | -5.8% | +4.7% | +3.9% | +10.2% | +7.7% | +7.5% | -17.5% | +9.9% | +10.1% | +240.7% | -65.7% | – | – | +70.3% | – | – | – | +9.6% | +5.7% | +30.5% | +11.4% | +0.0% | – | |
| – | -171.7% | – | -102.1% | – | +70.0% | -46.8% | +100.4% | +14.7% | -28.2% | +19.9% | +46.0% | +14.9% | +0.0% | +40.6% | -10.1% | +53.6% | -37.2% | +16.3% | -6.3% | +16.7% | -1.2% | +7.1% | -35.7% | -55.3% | -2.7% | -37.0% | -1,982.7% | – | -2,212.5% | – | -146.3% | – | – | – | – | – | – | – | – | – | |
| – | -22.1% | +20.5% | -12.8% | +118.0% | -3.4% | +14.6% | -6.1% | +39.1% | +20.9% | -26.6% | -1.4% | -27.8% | +14.0% | -31.7% | +18.9% | +6.1% | +9.5% | -3.1% | -8.7% | +27.0% | +29.3% | +17.3% | +45.0% | -11.1% | -13.4% | +529.2% | +39.2% | +5.3% | +7.6% | -12.0% | +39.2% | +61.4% | +7.1% | -11.8% | +7.2% | +67.1% | +61.9% | -38.5% | +6.4% | – | |
| – | +10.1% | -7.4% | -5.1% | -6.3% | +55.8% | -34.6% | +17.1% | -20.5% | +98.6% | -37.4% | +13.2% | -0.2% | -9.1% | +9.8% | -2.4% | +7.8% | +8.1% | -14.5% | +5.8% | +4.8% | +10.9% | +20.5% | +0.1% | +96.8% | -30.0% | +222.3% | -29.0% | -5.8% | -9.0% | +37.6% | -6.2% | +26.5% | +18.2% | -4.9% | -1.7% | +0.3% | -10.1% | +0.5% | +11.6% | – | |
| – | -13.4% | +34.5% | -8.9% | +13.8% | +40.4% | -23.0% | +10.0% | -2.6% | +44.1% | -27.3% | +8.6% | -7.8% | -1.0% | +2.4% | -2.8% | +11.9% | +0.3% | -13.3% | +4.1% | +4.3% | +14.6% | +15.5% | +7.6% | +52.4% | -22.0% | +217.8% | -56.6% | +134.1% | -77.9% | +282.4% | +32.2% | +43.6% | +141.4% | -59.2% | +28.7% | +15.7% | +45.9% | -31.6% | +7.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -62.3% | +0.0% | -69.0% | +144.4% | +1,722.7% | -98.3% | +1,071.4% | -8.5% | -80.0% | +140.0% | +352.8% | -87.7% | +1,090.0% | -98.7% | +1,200.0% | -97.4% | +9,300.0% | +43.6% | +56.3% | -85.3% | +1,751.6% | -75.6% | +185.7% | -65.0% | +185.7% | -95.5% | +44.4% | +7.7% | -14.3% | -41.7% | +107.1% | +137.9% | +5.8% | -5.5% | +72.5% | -45.4% | -1.5% | +64.1% | -32.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -1,922.7% | – | – | -8.5% | -120.0% | – | – | – | – | – | – | -102.6% | – | – | – | – | – | – | – | – | – | – | – | – | +2,723.4% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.